SEP 03, 2015 6:00 AM PDT

MRSA Screening Program at a Community Healthcare System

Presented at: Microbiology
Speaker
  • Clinical Scientist in Microbiology, Immunology, and Molecular, Pathology Consultants of South Broward, LLP, Memorial Healthcare System
    Biography
      Rodney Arcenas earned a B.S. with Honors in Microbiology from the University of Florida in the spring of 1997. He continued his Microbiology training at the University Of South Florida College Of Medicine graduating in 2002 with a M.S. and Ph.D. in Medical Microbiology and Immunology. Dr. Arcenas was then accepted into the Clinical Microbiology Fellowship program at the Mayo Clinic in Rochester, MN. After completing his fellowship, he was hired in 2004 at LabOne, Inc. in Lenexa, Kansas to be their Scientific Director of Microbiology and Immunology. He left LabOne, Inc. in 2006 to join the Pathology Consultants of South Broward (PCSB) as their Clinical Scientist for Microbiology/Molecular Testing and has been there since. In his time with PCSB, Dr. Arcenas has helped to start the Molecular Infectious Disease testing service that has grown from a day-shift (8-hr, Mon - Fri) operation with 2 Medical Technologists to having 5 full time and 3 part time Medical Technologists with 24-hr shifts (Mon - Fri) and an abbreviated 1.5 shifts on the weekends. He also has helped spearhead the implementation of a successful MRSA active surveillance program that started in 2008. Dr. Arcenas is board certified as a Diplomate of the American Board of Medical Microbiology.

    Abstract

    Healthcare-associated infections (HAIs) continue to be a considerable problem for hospitals and healthcare institutions that can adversely affect patient outcomes and impact the financial bottom lines. There are a number of strategies hospitals may implement for combating and controlling HAIs. Methicillin Resistant Staphylococcus aureus (MRSA) is one of those HAIs that can cause significant morbidity and mortality. Minimizing or eliminating the potential for infection is one main driver for a hospital to consider and develop a screening/surveillance program. Other factors include pressures from states passing legislation requiring a MRSA program to be implemented and CMS's initiatives to prevent HAIs in general. The scope and clinical utility of a MRSA screening or active surveillance program is institution dependent and an assessment of the MRSA prevalence will help drive the decision to implement a formal Infection Control program. The identification of MRSA colonized patients is critical in directing Infection Control efforts towards limiting the risk of infection, and decreasing the likelihood that MRSA colonized patients become reservoirs of infection that could potentially be transmitted to other patients via the healthcare worker. In this presentation, we describe our successes and other lessons learned during our experiences in developing and implementing an active surveillance MRSA program in a large community healthcare system.


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    NOV 18, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    JUN 09, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 09, 2020 10:00 AM PDT
    DATE: June 9, 2020 TIME: 10:00am PT, 1:00pm ET The presentation will first discuss sepsis as a disease and then explain the importance of performing diagnostic tests in the clinical labora...
    C.E. CREDITS
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    SEP 03, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 03, 2020 9:00 AM PDT
    DATE: September 3, 2020 TIME: 09:00am PT, 12:00pm ET xxx Learning Objectives: xxx Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provi...
    JUN 17, 2020 1:30 PM PDT
    C.E. CREDITS
    JUN 17, 2020 1:30 PM PDT
    Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
    Loading Comments...
    Show Resources
    Attendees
    • See more